Hu23F2G

A Phase 3 trial was conducted using the human antileukocyte antibody Hu23F2G, developed by ICOS Corporation. Because it is a human antibody and not a murine antibody, it was hoped that this agent would avoid the unwanted immune effects of enlimomab. Hu23F2G did not appear to produce the immune response seen with enlimomab. However, no clinical benefit was seen on any of the planned measures (28). No further studies with this agent are planned, although smaller antibodies that target specific leukocyte receptors might still have potential.

Metabolism Masterclass

Metabolism Masterclass

Are You Sick And Tired Of All The Fat-Burning Tricks And Trends That Just Don’t Deliver? Well, Get Set To Discover The Easy, Safe, Fast, And Permanent Way To Mega-Charge Your Metabolism And Lose Excess Fat Once And For All! This Weight Blasting Method Is Easy AND Natural… And Will Give You The Hot Body And Killer Energy Levels You’ve Been Dreaming Of.

Get My Free Ebook


Post a comment